A Phase 1/2 interventional study of PBCAR20A and Fludarabine in Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse and Non-Hodgkin's Lymphoma Refractory, sponsored by Precision BioSciences, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-31.
Sponsored by Precision BioSciences, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing fludarabine in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, none of them phase 3. fludarabine · Lymphoma, Non-Hodgkin.
Among the 94 studies testing fludarabine in Lymphoma, Non-Hodgkin, this one is the 69th largest by enrollment, is one of 3 that started in 2020, is one of 12 in phase 1/2, and was the 87th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 94 studies testing fludarabine in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
Essen Biotech · Sites in China
Ages 8–85
Fred Hutchinson Cancer Center · Sites in United States
Ages 6 mo–65 yrs
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 21
Hebei Senlang Biotechnology Inc., Ltd. · Sites in China
Ages 14–75
By country, each count listing its studies:
fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 66 · Phase 3 5
First in 1998; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 37 across the 94 interventional studies. Of the 78 that completed or were terminated, 50 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 94 have an industry lead sponsor. The 10 most frequent:
Precision BioSciences, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Precision BioSciences, Inc. has 1 study filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
1 of the studies testing fludarabine in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04644016Memorial Sloan Kettering Cancer CenterCord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | 2026-12-20 |
Add it to your calendar (.ics) → With an account.
Among the 94 studies testing fludarabine in Lymphoma, Non-Hodgkin, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.
This is a multicenter, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate safety, tolerability, clinical activity, and find an appropriate dose to optimize safety and efficacy of PBCAR20A in subjects with relapsed/refractory (r/r) CD20+ Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Before initiating PBCAR20A, therapy, subjects will be administered lymphodepletion chemotherapy composed of fludarabine and cyclophosphamide. At Day 0 of the Treatment Period, subjects will receive a single intravenous (IV) infusion of PBCAR20A. All subjects are monitored during the treatment period through Day 28. All subjects who receive a dose of PBCAR20A will be followed in a separate long-term follow-up (LTFU) study for 15 years after exiting this study.
Key Inclusion Criteria
Criteria for NHL:
Criteria for CLL/SLL:
Criteria for both NHL and CLL/SLL:
Key Exclusion Criteria:
Criteria for NHL:
Criteria for NHL and CLL/SLL:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 x 10\^6 chimeric antigen receptor (CAR) T cells per kg body weight. In this study, PBCAR20A, allogeneic anti-cluster of differentiation (CD20) CAR T Cells, is used to treat patients with relapsed or refractory (r/r) CD20+ Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Route of Administration: Intravenous infusion (IV) Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR20A infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion.
Genetic: PBCAR20A · Drug: Fludarabine · Drug: Cyclophosphamide
240 x 10\^6 CAR T cells (flat dose)
Genetic: PBCAR20A · Drug: Fludarabine · Drug: Cyclophosphamide
480 x 10\^6 CAR T cells (flat dose)
Genetic: PBCAR20A · Drug: Fludarabine · Drug: Cyclophosphamide
Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic "3+3" dose escalation will be applied.
Also known as: Allogeneic Anti-CD20 CAR T cells
Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
Maximum Tolerated Dose (MTD)
The maximum tolerated dose (MTD) is the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.
Time frame: Day 1 to Day 28
Number of Participants With Dose-Limiting Toxicities
Dose-limiting toxicities (DLT) are certain Grade 3 and Grade 4 toxic reactions as defined by the protocol and CTCAE v5.0.
Time frame: 1 year
Objective Response Rate
Objective response rate (ORR) is a measure of clinical activity as response in NHL by the revised Lugano Classification (Cheson et al, 2016) or a response in CLL/SLL by the International Workshop on Chronic Lymphocytic Leukemia 2018 guidelines.
Time frame: 1 year
Progression-free Survival (PFS)
Progression-free survival is defined as the duration (days) from Day 0 to disease progression or death.
Time frame: 1 year
| Milestone | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells |
|---|---|---|---|
| Started | 8 | 3 | 7 |
| Participants in demographic population | 8 | 3 | 6 |
| Participants in safety population | 8 | 3 | 6 |
| Participants re-treated | 0 | 0 | 1 |
| Participants in efficacy population | 8 | 3 | 7 |
| Completed | 6 | 3 | 7 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
The maximum tolerated dose (MTD) is the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.
| 10^6 CAR T cells | PBCAR20A CAR T Cells |
|---|---|
| Maximum Tolerated Dose (MTD) | NA |
Dose-limiting toxicities (DLT) are certain Grade 3 and Grade 4 toxic reactions as defined by the protocol and CTCAE v5.0.
| Participants | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells |
|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities | 1 | 0 | 0 |
Objective response rate (ORR) is a measure of clinical activity as response in NHL by the revised Lugano Classification (Cheson et al, 2016) or a response in CLL/SLL by the International Workshop on Chronic Lymphocytic Leukemia 2018 guidelines.
| Participants | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells |
|---|---|---|---|
| Responders | 2 | 1 | 3 |
| Complete Response | 1 | 0 | 0 |
| Partial Response | 1 | 1 | 3 |
| Non-responders | 6 | 2 | 4 |
Progression-free survival is defined as the duration (days) from Day 0 to disease progression or death.
| Days | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells |
|---|---|---|---|
| Progression-free Survival (PFS) | 29.5 (15.0 to 365.0) | 29.0 (29.0 to 94.0) | 29.0 (12.0 to 66.0) |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 of PBCAR20A CAR T Cells | 1/8 (12.5%) | 3/8 (37.5%) | 8/8 (100%) |
| Dose Level 2 of PBCAR20A CAR T Cells | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Level 3 of PBCAR20A CAR T Cells | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/8 | 0/3 | 1/6 |
| Abdominal painGastrointestinal disorders | 1/8 | 0/3 | 0/6 |
| PneumoniaInfections and infestations | 1/8 | 0/3 | 0/6 |
| SepsisInfections and infestations | 1/8 | 0/3 | 0/6 |
| Transaminases increasedInvestigations | 1/8 | 0/3 | 0/6 |
| CAR T cell-related encephalopathy syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/8 | 0/3 | 0/6 |
| Event | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 6/8 | 1/3 | 3/6 |
| Neutrophil count decreasedInvestigations | 6/8 | 2/3 | 4/6 |
| ConstipationGastrointestinal disorders | 1/8 | 2/3 | 2/6 |
| NauseaGastrointestinal disorders | 3/8 | 2/3 | 2/6 |
| FatigueGeneral disorders | 4/8 | 2/3 | 1/6 |
| Oedema peripheralGeneral disorders | 3/8 | 1/3 | 4/6 |
| PyrexiaGeneral disorders | 4/8 | 2/3 | 3/6 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/8 | 2/3 | 0/6 |
| HeadacheNervous system disorders | 1/8 | 2/3 | 2/6 |
| Cytokine release syndromeImmune system disorders | 1/8 | 1/3 | 3/6 |
| Age, Continuous(years) | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells | Total |
|---|---|---|---|---|
| Mean | 58.25 ± 17.07 | 47.00 ± 19.08 | 58.17 ± 13.70 | 56.24 ± 15.85 |
| Sex: Female, Male(Participants) | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells | Total |
|---|---|---|---|---|
| Female | 2 | 0 | 1 | 3 |
| Male | 6 | 3 | 5 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 3 |
| Not Hispanic or Latino | 7 | 1 | 6 | 14 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 7 | 2 | 5 | 14 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Dose Level 1 of PBCAR20A CAR T Cells | Dose Level 2 of PBCAR20A CAR T Cells | Dose Level 3 of PBCAR20A CAR T Cells | Total |
|---|---|---|---|---|
| United States | 8 | 3 | 6 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in Jun 2021, 15 months.
Results were first posted in Jan 2023, 1 year 7 months after primary completion.
Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 15 months is below that.
Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fludarabine · Cyclophosphamide
Precision BioSciences, Inc.